Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week Low - Time to Sell?

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report)'s share price hit a new 52-week low on Monday . The company traded as low as $9.92 and last traded at $10.15, with a volume of 451980 shares traded. The stock had previously closed at $10.38.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ROIV shares. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.

Roivant Sciences Price Performance

The firm has a fifty day simple moving average of $10.65 and a 200-day simple moving average of $11.35. The firm has a market cap of $6.75 billion, a P/E ratio of -63.06 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Activity

In related news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction dated Monday, January 13th. The stock was purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,395,541 shares of company stock worth $15,028,538 over the last three months. 7.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of ROIV. Nordea Investment Management AB raised its holdings in shares of Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company's stock valued at $3,306,000 after purchasing an additional 52,031 shares during the last quarter. Barclays PLC boosted its holdings in Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Retirement Systems of Alabama grew its position in Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after purchasing an additional 112,286 shares in the last quarter. Elevate Capital Advisors LLC purchased a new stake in Roivant Sciences in the 4th quarter valued at about $2,116,000. Finally, State Street Corp lifted its position in shares of Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company's stock worth $225,737,000 after buying an additional 1,118,561 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.